Keywords
How to Cite
Abstract
The high rates of pathologic complete response (pCR) after modern systemic therapy observed in patients with HER2-positive and triple-negative breast cancer led to the fact that there was a tendency to reduce surgical activity up to the complete refusal of breast surgery subject to the assessment of complete pathological regression using both radiation diagnostic methods and methods of morphological verification of the tumor bed, such as vacuum-assisted biopsy , and accurate core needle biopsy.
This review article summarizes all available data on how to morphologically assess complete pathomorphological response (p CR) after neoadjuvant systemic therapy using core needle biopsies and vacuum-assisted biopsy .
References
Heil J, Kuerer HM, Pfob A et al. Eliminating the breast cancer surgery paradigm after neoadjuvant systemic therapy: current evidence and future challenges // Ann Oncol. 2020;31(1):61–71. doi:10.1016/j.annonc.2019.10.012
Murphy BL, Day CN, Hoskin TL et al. Neoadjuvant Chemotherapy Use in Breast Cancer is Greatest in Excellent Responders: Triple-Negative and HER2+ Subtypes // Ann Surg Oncol. 2018;25(8):2241–2248. doi:10.1245/s10434-018-6531-5
Cortazar P, Zhang L, Untch M et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis // Lancet. 2014;384(9938):164–172. doi:10.1016/S0140-6736(13)62422-8
Symmans WF, Wei C, Gould R et al. Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype // J Clin Oncol. 2017;35(10):1049–1060. doi:10.1200/JCO.2015.63.1010
Haque W, Verma V, Hatch S et al. Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy // Breast Cancer Res Treat. 2018;170(3):559–567. doi:10.1007/s10549-018-4801-3
Goorts B, van Nijnatten TJ, de Munck L et al. Clinical tumor stage is the most important predictor of pathological complete response rate after neoadjuvant chemotherapy in breast cancer patients // Breast Cancer Res Treat. 2017;163(1):83–91. doi:10.1007/s10549-017-4155-2
Semiglazov VF, Topuzov EE, Bavli JL et al. Primary (neoadjuvant) chemotherapy and radiotherapy compared with primary radiotherapy alone in stage IIb–IIIa breast cancer // Ann Oncol. 1994;5(7):591–595. doi:10.1093/oxfordjournals.annonc.a058929
Cortazar P, Semiglazov V et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis // The Lancet. 2014;384:9938:164–172
van Ramshorst MS, van der Voort A, van Werkhoven ED et al. Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial // Lancet Oncol. 2018;19(12):1630–1640. doi:10.1016/S1470-2045(18)30570-9
Santonja A, Sánchez-Muñoz A, Lluch A et al. Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy // Oncotarget. 2018;9(41):26406–26416. doi:10.18632/oncotarget.25413
Samiei S, van Nijnatten TJA, de Munck L et al. Correlation Between Pathologic Complete Response in the Breast and Absence of Axillary Lymph Node Metastases After Neoadjuvant Systemic Therapy // Ann Surg. 2020;271(3):574–580. doi:10.1097/SLA.0000000000003126
Barron AU, Hoskin TL, Day CN et al. Association of Low Nodal Positivity Rate Among Patients With ERBB2-Positive or Triple-Negative Breast Cancer and Breast Pathologic Complete Response to Neoadjuvant Chemotherapy // JAMA Surg. 2018;153(12):1120–1126. doi:10.1001/jamasurg.2018.2696
Tadros AB, Yang WT, Krishnamurthy S et al. Identification of Patients With Documented Pathologic Complete Response in the Breast After Neoadjuvant Chemotherapy for Omission of Axillary Surgery // JAMA Surg. 2017;152(7):665–670. doi:10.1001/jamasurg.2017.0562
Morrow M, Khan AJ. Locoregional Management After Neoadjuvant Chemotherapy // J Clin Oncol. 2020;38(20):2281–2289. doi:10.1200/JCO.19.02576
Patey DH, Dyson WH. The prognosis of carcinoma of the breast in relation to the type of operation performed // Br J Cancer. 1948;2(1):7–13. doi:10.1038/bjc.1948.2
Madden JL. Modified radical mastectomy // Surg Gynecol Obstet. 1965;121(6):1221–1230
Sakorafas GH, Safioleas M. Breast cancer surgery: an historical narrative. Part III. From the sunset of the 19th to the dawn of the 21st century // Eur J Cancer Care (Engl). 2010;19(2):145–166. doi:10.1111/j.1365-2354.2008.01061.x
Blichert-Toft M, Rose C, Andersen JA et al. Danish randomized trial comparing breast conservation therapy with mastectomy: six years of life-table analysis. Danish Breast Cancer Cooperative Group // J Natl Cancer Inst Monogr. 1992;(11):19–25.
Semiglazov VF et al. Breast-conserving surgery after neoadjuvant therapy for breast cancer // Voprosy onkologii. 2015;61(3):381–386.
Fisher B, Redmond C, Poisson R et al. Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer // N Engl J Med. 1989;320(13):822–828. doi:10.1056/NEJM198903303201302
Veronesi U, Salvadori B, Luini A et al. Conservative treatment of early breast cancer. Long-term results of 1232 cases treated with quadrantectomy, axillary dissection, and radiotherapy // Ann Surg. 1990;211(3):250–259.
Lichter AS, Lippman ME, Danforth DNJr et al. Mastectomy versus breast-conserving therapy in the treatment of stage I and II carcinoma of the breast: a randomized trial at the National Cancer Institute // J Clin Oncol. 1992;10(6):976–983. doi:10.1200/JCO.1992.10.6.976
van Dongen JA, Bartelink H, Fentiman IS et al. Randomized clinical trial to assess the value of breast-conserving therapy in stage I and II breast cancer, EORTC 10801 trial // J Natl Cancer Inst Monogr. 1992;(11):15–18.
Sarrazin D, Lê MG, Arriagada R et al. Ten-year results of a randomized trial comparing a conservative treatment to mastectomy in early breast cancer // Radiother Oncol. 1989;14(3):177–184. doi:10.1016/0167-8140(89)90165-5
Fisher B, Anderson S, Bryant J et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer // N Engl J Med. 2002;347(16):1233–1241. doi:10.1056/NEJMoa022152
van Dongen JA, Voogd AC, Fentiman IS et al. Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial // J Natl Cancer Inst. 2000;92(14):1143–1150. doi:10.1093/jnci/92.14.1143
Veronesi U, Cascinelli N, Mariani L et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer // N Engl J Med. 2002;347(16):1227–1232. doi:10.1056/NEJMoa020989
Poggi MM, Danforth DN, Sciuto LC et al. Eighteen-year results in the treatment of early breast carcinoma with mastectomy versus breast conservation therapy: the National Cancer Institute Randomized Trial // Cancer. 2003;98(4):697–702. doi:10.1002/cncr.11580
Arriagada R, Lê MG, Rochard F, Contesso G. Conservative treatment versus mastectomy in early breast cancer: patterns of failure with 15 years of follow-up data. Institut Gustave-Roussy Breast Cancer Group // J Clin Oncol. 1996;14(5):1558–1564. doi:10.1200/JCO.1996.14.5.1558
Jatoi I, Proschan MA. Randomized trials of breast-conserving therapy versus mastectomy for primary breast cancer: a pooled analysis of updated results // Am J Clin Oncol. 2005;28(3):289–294. doi:10.1097/01.coc.0000156922.58631.d7
Международные реокщмендации по лечению раннего рака молочной железы: рук. для врачей / Под ред. В.Ф. Семиглазова. М.: МК, 2020.
Burstein HJ, Curigliano G, Loibl S et al. Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019 // Ann Oncol. 2019;30(10):1541–1557. doi:10.1093/annonc/mdz235
Rubens RD, Sexton S, Tong D et al. Combined chemotherapy and radiotherapy for locally advanced breast cancer // Eur J Cancer. 1980;16(3):351–356. doi:10.1016/0014-2964(80)90352-7
Rastogi P, Anderson SJ, Bear HD et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27 // J Clin Oncol. 2008;26(5):778–785. doi:10.1200/JCO.2007.15.0235
Bonadonna G, Veronesi U, Brambilla C et al. Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more // J Natl Cancer Inst. 1990;82(19):1539–1545. doi:10.1093/jnci/82.19.1539
Fisher B, Brown A, Mamounas E et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18 // J Clin Oncol. 1997;15(7):2483–2493. doi:10.1200/JCO.1997.15.7.2483
van der Hage JA, van de Velde CJ, Julien JP et al. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902 // J Clin Oncol. 2001;19(22):4224–4237. doi:10.1200/JCO.2001.19.22.4224
Golshan M, Cirrincione CT, Sikov WM et al. Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II–III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance) // Breast Cancer Res Treat. 2016;160(2):297–304. doi:10.1007/s10549-016-4006-6
Golshan M, Cirrincione CT, Sikov WM et al. Impact of neoadjuvant chemotherapy in stage II–III triple negative breast cancer on eligibility for breast-conserving surgery and breast conservation rates: surgical results from CALGB 40603 (Alliance) // Ann Surg. 2015;262(3):434–439. doi:10.1097/SLA.0000000000001417
Semiglazov VF, Semiglazov V, Ivanov V et al. The relative efficacy of neoadjuvant endocrine therapy vs chemotherapy in postmenopausal women with ER- positive breast cancer // Journal of Clinical Oncology. 2004 22:14(suppl):519–519.
Bear HD, Anderson S, Brown A et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27 // J Clin Oncol. 2003;21(22):4165–4174. doi:10.1200/JCO.2003.12.005
Criscitiello C, Golshan M, Barry WT et al. Impact of neoadjuvant chemotherapy and pathological complete response on eligibility for breast-conserving surgery in patients with early breast cancer: A meta-analysis // Eur J Cancer. 2018;97:1–6. doi:10.1016/j.ejca.2018.03.023
Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials // Lancet Oncol. 2018;19(1):27–39. doi:10.1016/S1470-2045(17)30777-5
Swisher SK, Vila J, Tucker SL et al. Locoregional Control According to Breast Cancer Subtype and Response to Neoadjuvant Chemotherapy in Breast Cancer Patients Undergoing Breast-conserving Therapy // Ann Surg Oncol. 2016;23(3):749–756. doi:10.1245/s10434-015-4921-5
Cortazar P, Zhang L, Untch M et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis // Lancet. 2014;384(9938):164–172. doi:10.1016/S0140-6736(13)62422-8
Valachis A, Mamounas EP, Mittendorf EA et al. Risk factors for locoregional disease recurrence after breast-conserving therapy in patients with breast cancer treated with neoadjuvant chemotherapy: An international collaboration and individual patient meta-analysis // Cancer. 2018;124(14):2923–2930. doi:10.1002/cncr.31518
von Minckwitz G, Untch M, Blohmer JU et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes // J Clin Oncol. 2012;30(15):1796–1804. doi:10.1200/JCO.2011.38.8595
Schaefgen B, Mati M, Sinn HP et al. Can Routine Imaging After Neoadjuvant Chemotherapy in Breast Cancer Predict Pathologic Complete Response? // Ann Surg Oncol. 2016;23(3):789–795. doi:10.1245/s10434-015-4918-0
Heil J, Kuerer HM, Pfob A et al. Eliminating the breast cancer surgery paradigm after neoadjuvant systemic therapy: current evidence and future challenges // Ann Oncol. 2020;31(1):61–71. doi:10.1016/j.annonc.2019.10.012
Криворотько П.В. и др. К вопросу об интерпретации результатов сцинтиграфии с 99m Tc-Технетрилом у больных РМЖ // Эффективная фармакотерапия. 2013(6.):24–31.
National Collaborating Centre for Cancer (UK). Early and Locally Advanced Breast Cancer: Diagnosis and Treatment. Cardiff (UK): National Collaborating Centre for Cancer (UK); February 2009
Semiglazov V. How to handle breast cancer patient with complete response following neoadjuvant chemotherapy? // EJSO. 2008;1025.
Kuerer HM, Vrancken Peeters MTFD, Rea DW et al. Nonoperative Management for Invasive Breast Cancer After Neoadjuvant Systemic Therapy: Conceptual Basis and Fundamental International Feasibility Clinical Trials // Ann Surg Oncol. 2017;24(10):2855–2862. doi:10.1245/s10434-017-5926-z
Krag DN, Anderson SJ, Julian TB et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial // Lancet Oncol. 2010;11(10):927–933. doi:10.1016/S1470-2045(10)70207-2
Fowler AM, Mankoff DA, Joe BN. Imaging Neoadjuvant Therapy Response in Breast Cancer // Radiology. 2017;285(2):358–375. doi:10.1148/radiol.2017170180
Li H, Yao L, Jin P et al. MRI and PET/CT for evaluation of the pathological response to neoadjuvant chemotherapy in breast cancer: A systematic review and meta-analysis // Breast. 2018;40:106–115. doi:10.1016/j.breast.2018.04.018
Rauch GM, Adrada BE, Kuerer HM et al. Multimodality Imaging for Evaluating Response to Neoadjuvant Chemotherapy in Breast Cancer // AJR Am J Roentgenol. 2017;208(2):290–299. doi:10.2214/AJR.16.17223
Schaefgen B, Mati M, Sinn HP et al. Can Routine Imaging After Neoadjuvant Chemotherapy in Breast Cancer Predict Pathologic Complete Response? // Ann Surg Oncol. 2016;23(3):789–795. doi:10.1245/s10434-015-4918-0
von Minckwitz G, Huang CS, Mano MS et al. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer // N Engl J Med. 2019;380(7):617–628. doi:10.1056/NEJMoa1814017
Heil J, Kümmel S, Schaefgen B et al. Diagnosis of pathological complete response to neoadjuvant chemotherapy in breast cancer by minimal invasive biopsy techniques // Br J Cancer. 2015;113:1565–1570. doi:10.1038/bjc.2015.381
Kuerer HM, Rauch GM, Krishnamurthy S et al. A Clinical Feasibility Trial for Identification of Exceptional Responders in Whom Breast Cancer Surgery Can Be Eliminated Following Neoadjuvant Systemic Therapy // Ann Surg. 2018;267(5):946–951. doi:10.1097/SLA.0000000000002313
Heil J, Richter H, Golatta M, Sinn HP. Vacuum-Assisted Biopsy to Diagnose a Pathological Complete Response in Breast Cancer Patients After Neoadjuvant Systemic Therapy // Ann Surg. 2018;268(6):e60–e61. doi:10.1097/SLA.0000000000002572
Abstract GS5-05: Primary analysis of NRG-BR005, a phase II trial assessing accuracy of tumor bed biopsies in predicting pathologic complete response (pCR) in patients with clinical/radiological complete response after neoadjuvant chemotherapy (NCT) to explore the feasibility of breast-conserving treatment without surgery. Mark Basik, Reena S Cecchini, Jennifer F De Los Santos, Heidi R Umphrey, Thomas B Julian, Eleftherios P Mamounas, Julia White, Peter C Lucas, Christa Balanoff, Antoinette R Tan, Joseph J. Weber, David A Edmonson, Ursa A. Brown-Glaberman, Emilia J. Diego, Mediget Teshome, Cindy B Matsen, Samantha A Seaward, Irene L. Wapnir, Jamie L Wagner, Judy A Tjoe, Alastair M Thompson and Norman Wolmark // Cancer Res. 2020;80(Suppl. 4):GS5–05. doi:10.1158/1538-7445.SABCS19-GS5-05
van Loevezijn AA, van der Noordaa MEM, van Werkhoven ED et al. Minimally Invasive Complete Response Assessment of the Breast After Neoadjuvant Systemic Therapy for Early Breast Cancer (MICRA trial): Interim Analysis of a Multicenter Observational Cohort Study // Ann Surg Oncol. 2021;28(6):3243–3253. doi:10.1245/s10434-020-09273-0
Tasoulis MK, Lee HB, Yang W et al. Accuracy of Post-Neoadjuvant Chemotherapy Image-Guided Breast Biopsy to Predict Residual Cancer // JAMA Surg. 2020;155(12):e204103. doi:10.1001/jamasurg.2020.4103
Gärtner R, Jensen MB, Nielsen J et al. Prevalence of and factors associated with persistent pain following breast cancer // JAMA. 2009;302(18):1985-1992. doi:10.1001/jama.2009.1568
Flanagan MR, Zabor EC, Romanoff A et al. A Comparison of Patient-Reported Outcomes After Breast-Conserving Surgery and Mastectomy with Implant Breast Reconstruction // Ann Surg Oncol. 2019;26(10):3133–3140. doi:10.1245/s10434-019-07548-9
Gent HJ, Sprenger E, Dowlatshahi K. Stereotaxic needle localization and cytological diagnosis of occult breast lesions // Ann Surg. 1986;204(5):580–584. doi:10.1097/00000658-198611000-00012
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2022